Novartis: EU approves Xolair for self-administration

(CercleFinance.com) - The European Commission has approved Novartis' asthma injectable drug Xolair for self-administration across all indications, the drugmaker said on Thursday.


The European Commission has approved Xolair pre-filled syringes so that patients with severe allergic asthma and chronic spontaneous urticaria can administer their own treatment, the Swiss group said.

Administered via injection every two-to-four weeks, Xolair is an antibody that is designed to target and block immunoglobulin E, minimising allergic inflammatory reactions.

Copyright (c) 2018 CercleFinance.com. All rights reserved.